KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Leases (2019 - 2025)

Travere Therapeutics' Leases history spans 7 years, with the latest figure at $10.6 million for Q4 2025.

  • For Q4 2025, Leases fell 26.02% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, down 26.02%, while the annual FY2025 figure was $10.6 million, 26.02% down from the prior year.
  • Leases reached $10.6 million in Q4 2025 per TVTX's latest filing, down from $11.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $25.0 million in Q1 2021 to a low of $10.6 million in Q4 2025.
  • Average Leases over 5 years is $18.6 million, with a median of $19.2 million recorded in 2023.
  • Peak YoY movement for Leases: plummeted 32.96% in 2021, then fell 9.47% in 2022.
  • A 5-year view of Leases shows it stood at $23.2 million in 2021, then dropped by 9.47% to $21.0 million in 2022, then decreased by 14.0% to $18.1 million in 2023, then fell by 20.85% to $14.3 million in 2024, then dropped by 26.02% to $10.6 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Leases are $10.6 million (Q4 2025), $11.5 million (Q3 2025), and $12.3 million (Q2 2025).